← All trials
NCT05263271
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2021
- Primary completion
- Jul 30, 2024
- Completion date
- Jul 30, 2024
- First posted
- Mar 2, 2022
- Last posted
- Mar 2, 2022
- Enrollment
- 58
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- GeneScience Pharmaceuticals Co., Ltd.Lead sponsor
- Zhejiang UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Jiao Tong UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.